Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors

US12036279B2 · kind B2 · utility

Assignee

• Memorial Sloan Kettering Cancer Center · US

Inventors

• Liang Deng · New York, US
• Stewart Shuman · New York, US
• Jedd D. Wolchok · New York, US
• Taha Merghoub · New York, US
• Weiyi Wang · Hangzhou City, CN
• Peihong Dai · New York, US
• Ning-Sun Yang · Taipei, TW

Key dates

• Filing date: Feb 25, 2022
• Grant date: Jul 16, 2024
• Expiry date: Feb 25, 2042

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVAΔE3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.